Bulevirtide: First Approval
Any type of resource available online.
(Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the
treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus
(HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment
of chronic HDV infection in HDV RNA positive adult patients
with compensated liver disease. This
article summarizes the milestones in the development of bulevirtide leading to
this first approval for chronic HDV.
© Springer Nature Switzerland AG 2020